NEWS & EVENTS

 

Cambridge Enterprise signs deal with Qkine Ltd to drive stem cell and regenerative medicine research

 
Cambridge Enterprise signs deal with Qkine Ltd to drive stem cell and regenerative medicine research

08 August 2017

Cambridge Enterprise, the commercialisation arm of the University of Cambridge, has licensed key technology to specialist growth factor manufacturer Qkine Ltd for Activin A production.

Qkine Ltd is a recent spin-out from the biochemistry department at the University of Cambridge. The company builds on protein production technologies for regenerative medicine.

This deal relates to Activin A production technology. The technology, which was developed by one of Qkine’s founders, Dr Marko Hyvönen, will be used to manufacture proteins that are used for the control of stem cell growth and differentiation.

Read the full press release.

Partner Nick Sutcliffe works with Cambridge Enterprise on their IP portfolio and has done patent work on the licensed Activin A technology.